By using cutting-edge academic expertise and technology services to de-risk and improve the translation of academic and SME-driven developments towards the patient, EATRIS enhances biomedical innovation in Europe, and acts as an EU reference point where all stakeholders involved in the translational medicine value chain can work together.
Flagship efforts fostering innovation:
- EATRIS participation in IMI projects EU-PEARL and EPND as key partner leading the sustainability strategy.
- Glaxosmithkline (GSK) Imaging hub, developed and managed by EATRIS for GSK (large pharma) to deliver a clinical and scientific expert network for the development and application of innovative imaging methods for inflammatory diseases. The long-term collaboration between GSK and 6 EATRIS institutions represents more than €4mn of financing from GSK to our institutions.
- REMEDI4ALL, an ambitious EU-funded research initiative, coordinated by EATRIS and recently launched in 2022 to drive forward the repurposing of medicines in Europe (23M euros, 24 partners)
Additional efforts include the recent inception of EATRIS Expert Centres providing crucial but scarce knowledge to advance the development plan of translational projects – supporting innovation. These services cover a range of areas, such as innovation management, regulatory strategy, translational feasibility, and early health technology assessment.
Here are some examples of our work in this area:
